PURPOSE: Studies have demonstrated a synergistic effect between hyperthermia and chemotherapy, and clinical trials in image-guided drug delivery combine high-temperature thermal therapy (ablation) with chemotherapy agents released in the heating zone via low temperature sensitive liposomes (LTSL). The complex interplay between heat-based cancer treatments such as thermal ablation and chemotherapy may require computational models to identify the relationship between heat exposure and pharmacokinetics in order to optimise drug delivery. MATERIALS AND METHODS: Spatio-temporal data on tissue temperature and perfusion from heat-transfer models of radiofrequency ablation were used as input data. A spatio-temporal multi-compartmental pharmacokinetic model was built to describe the release of doxorubicin (DOX) from LTSL into the tumour plasma space, and subsequent transport into the extracellular space, and the cells. Systemic plasma and tissue compartments were also included. We compared standard chemotherapy (free-DOX) to LTSL-DOX administered as bolus at a dose of 0.7 mg/kg body weight. RESULTS: Modelling LTSL-DOX treatment resulted in tumour tissue drug concentration of approximately 9.3 microg/g with highest values within 1 cm outside the ablation zone boundary. Free-DOX treatment produced comparably uniform tissue drug concentrations of approximately 3.0 microg/g. Administration of free-DOX resulted in a considerably higher peak level of drug concentration in the systemic plasma compartment (16.1 microg/g) compared to LTSL-DOX (4.4 microg/g). These results correlate well with a prior in vivo study. CONCLUSIONS: Combination of LTSL-DOX with thermal ablation allows localised drug delivery with higher tumour tissue concentrations than conventional chemotherapy. Our model may facilitate drug delivery optimisation via investigation of the interplays among liposome properties, tumour perfusion, and heating regimen.
PURPOSE: Studies have demonstrated a synergistic effect between hyperthermia and chemotherapy, and clinical trials in image-guided drug delivery combine high-temperature thermal therapy (ablation) with chemotherapy agents released in the heating zone via low temperature sensitive liposomes (LTSL). The complex interplay between heat-based cancer treatments such as thermal ablation and chemotherapy may require computational models to identify the relationship between heat exposure and pharmacokinetics in order to optimise drug delivery. MATERIALS AND METHODS: Spatio-temporal data on tissue temperature and perfusion from heat-transfer models of radiofrequency ablation were used as input data. A spatio-temporal multi-compartmental pharmacokinetic model was built to describe the release of doxorubicin (DOX) from LTSL into the tumour plasma space, and subsequent transport into the extracellular space, and the cells. Systemic plasma and tissue compartments were also included. We compared standard chemotherapy (free-DOX) to LTSL-DOX administered as bolus at a dose of 0.7 mg/kg body weight. RESULTS: Modelling LTSL-DOX treatment resulted in tumour tissue drug concentration of approximately 9.3 microg/g with highest values within 1 cm outside the ablation zone boundary. Free-DOX treatment produced comparably uniform tissue drug concentrations of approximately 3.0 microg/g. Administration of free-DOX resulted in a considerably higher peak level of drug concentration in the systemic plasma compartment (16.1 microg/g) compared to LTSL-DOX (4.4 microg/g). These results correlate well with a prior in vivo study. CONCLUSIONS: Combination of LTSL-DOX with thermal ablation allows localised drug delivery with higher tumour tissue concentrations than conventional chemotherapy. Our model may facilitate drug delivery optimisation via investigation of the interplays among liposome properties, tumour perfusion, and heating regimen.
Authors: S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona Journal: Ann Surg Date: 1999-07 Impact factor: 12.969
Authors: J A Sparano; J Speyer; W J Gradishar; L Liebes; R Sridhara; S Mendoza; D Fry; M J Egorin Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Astrid Gasselhuber; Matthew R Dreher; Ari Partanen; Pavel S Yarmolenko; David Woods; Bradford J Wood; Dieter Haemmerich Journal: Int J Hyperthermia Date: 2012 Impact factor: 3.914
Authors: Ayele H Negussie; Pavel S Yarmolenko; Ari Partanen; Ashish Ranjan; Genevieve Jacobs; David Woods; Henry Bryant; David Thomasson; Mark W Dewhirst; Bradford J Wood; Matthew R Dreher Journal: Int J Hyperthermia Date: 2011 Impact factor: 3.914
Authors: Ashish Ranjan; Genevieve C Jacobs; David L Woods; Ayele H Negussie; Ari Partanen; Pavel S Yarmolenko; Carmen E Gacchina; Karun V Sharma; Victor Frenkel; Bradford J Wood; Matthew R Dreher Journal: J Control Release Date: 2011-12-21 Impact factor: 9.776